Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320970 · ClinicalTrials.gov registry record · NA
Angiotensin II Antagonism of TGF-Beta 1
A NA study, sponsored by Providence Health & Services.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00320970 is a NA study that has completed, run by Providence Health & Services. The registered enrollment target is 36 participants.
The verdict
NCT00320970, a NA study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Diabetic nephropathy is a frequent microvascular complication that occurs in approximately 40% of patients with either type 1 or type 2 diabetes. The most common cause of end-stage renal disease (ESRD) in the United States and in the developed world is diabetic nephropathy. Currently, more than half the United States ESRD population has diabetes. More effective therapies to prevent and treat diabetic nephropathy are urgently needed. One way to increase therapeutic effectiveness is to refine treatment targets based on improved understanding of how treatments modulate disease processes. The purpose of this study is to determine whether a treatment for diabetic nephropathy, the angiotensin receptor blocker candesartan, modifies mediators of kidney injury independent of blood pressure and the relationships to drug dose.
Interventions
- DRUG Candesartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-08 |
| Est. Completion | 2004-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320970
The ClinicalTrials.gov registry entry for NCT00320970 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Candesartan is the first listed.
NCT00320970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320970 about?
NCT00320970 is a clinical study titled "Angiotensin II Antagonism of TGF-Beta 1". Diabetic nephropathy is a frequent microvascular complication that occurs in approximately 40% of patients with either type 1 or type 2 diabetes. The most common cause of end-stage renal disease (ESRD) in the United States and in the developed world is diabetic nephropathy. Currently, more than half...
What is the current status of trial NCT00320970?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2002-08. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00320970?
The interventions under investigation include: Candesartan (DRUG).
Who is sponsoring clinical trial NCT00320970?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.